drugset
drugset / Trial / NCT07589608

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

NCT07589608 ↗

Phase 2 Recruiting 400 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Timeline

Start
2026-05-15
Primary completion
2027-09
Completion
2028-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Eloralintide Protein / enzyme biologic — Subcutaneous
Subject Macupatide Protein / enzyme biologic — Subcutaneous

Indications

obesity disorder